Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

European Innovation Council · Finished

mCUBE Multi-omic data driven drug discovery and indication prioritisation platform in oncology

Coordinator
Epigene Labs SAS, France
Runs
1 August 2022 to 31 July 2024
Status
Finished
EU funding
€2.5m
Total cost
€3.6m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
190185351

What the project is doing

In the project's own words, from its summary on CORDIS.

With 20 % of patients responding to their treatment and 10M dying every year, cancer is a recognised societal challenge. While data-driven approaches can double the clinical trials success rate, the pharma industry lacks tools to leverage the large amount of data generated in their drug discovery processes. We are developing mCUBE, an AI-powered platform that scales precision oncology for drug discovery and repurposing.

Best-in-class and user-centric platform, mCUBE encapsulates a cancer-agnostic clinical data harmonisation module with an integrative approach to multi-omic data analysis. As our solution increases in value and allows us to move up the value chain, our initial SaaS business model will progressively switch to a drug discovery model. With mCUBE, we will identify and validate new drug candidates to license IP assets to pharma companies.

By 2025, we expect to sign a deal of €25M with a biopharma partner. We will disrupt he oncology market for the benefits of cancer patients.

Topics

Who is involved

OrganisationCityCountryRole
Epigene Labs SASParisFranceCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI